대한두개안면성형외과학회지 (Archives of Craniofacial Surgery)

  • 제26권4호
  • /
  • Pages.147-153
  • /
  • 2025
  • /
  • 2287-1152(pISSN)
  • /
  • 2287-5603(eISSN)
대한두개안면성형외과학회 (Korean Association for Cranio Maxillo Facial Surgery)
권호 표지
DOI QR코드

DOI QR Code

Midface defects caused by mucormycosis with a new classification: a retrospective study

  • Hamid Reza Fathi (Department of Plastic, Reconstructive and Aesthetic Surgery, Tehran University of Medical Sciences) ;
  • Mohammad Mohammadi Arbati (Department of Plastic, Reconstructive and Aesthetic Surgery, Tehran University of Medical Sciences) ;
  • Seyed Mousa Sadrhosseini (Department of Otorhinolaryngology, Tehran University of Medical Sciences) ;
  • Mohammad Hadi Molseghi (Department of General Surgery, Ayatollah Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences) ;
  • Mahammad Davudov (Department of Oral and Maxillofacial Surgery, Azerbaijan Medical University)
  • 투고 : 2025.01.27
  • 심사 : 2025.08.19
  • 발행 : 2025.08.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The most complex and debated aspect of head and neck reconstructive surgery is the management of midface defects caused by malignant or non-malignant diseases. This study proposes a new classification system for patients with midface defects arising from non-malignant and non-traumatic diseases. Methods: In this study, 107 patients with midface defects resulting from mucormycosis were evaluated according to the anatomical locations of involvement and the differences between the affected areas. Results: Diabetes was identified as the most common underlying disease, while the paranasal sinuses were the most frequently involved sites in cases of mucormycosis. Fourteen patients developed mucormycosis without any associated risk factors, and one patient exhibited brain tissue involvement. Conclusion: To the best of our knowledge, this study is the first to present a comprehensive classification system for patients presenting with midface defects due to mucormycosis.

키워드

참고문헌

  1. Brown JS, Shaw RJ. Reconstruction of the maxilla and midface: introducing a new classification. Lancet Oncol 2010;11:1001-8. https://doi.org/10.1016/S1470-2045(10)70113-3
  2. Brown JS, Rogers SN, McNally DN, Boyle M. A modified classification for the maxillectomy defect. Head Neck 2000;22:17-26. https://doi.org/10.1002/(SICI)1097-0347(200001)22:1<17::AID-HED4>3.0.CO;2-2
  3. Cordeiro PG, Santamaria E. A classification system and algorithm for reconstruction of maxillectomy and midfacial defects. Plast Reconstr Surg 2000;105:2331-48. https://doi.org/10.1097/00006534-200006000-00004
  4. Metzen D, Bohm H, Zimmermann M, Reuther T, Kubler AC, Muller-Richter UD. Mucormycosis of the head and neck. J Craniomaxillofac Surg 2012;40:e321-7. https://doi.org/10.1016/j.jcms.2012.01.015
  5. Ojha T, Jain M, Gupta P. Single-stage reconstruction of maxillectomy and midfacial defects in cases of Covid associated mucormycosis. Indian J Otolaryngol Head Neck Surg 2022;74:3327-32. https://doi.org/10.1007/s12070-022-03121-1
  6. Srikanth V, Pradeep KN, Anantheswar YN, Ashok BC, Sudarsahn R, Bhath R. Cranio-facial mucormycosis: the plastic surgeon's perspective. Eur J Plast Surg 2020;43:239-46. https://doi.org/10.1007/s00238-019-01606-x
  7. Tomar K, Roy ID, Rangan M, Satyanarayan P, Jakka S. Post-Covid orofacial mucormycosis: a clinico-radiological classification system and management protocol. J Maxillofac Oral Surg 2023 Feb 3 [Epub]. https://doi.org/10.1007/s12663-022-01843-x
  8. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146. https://doi.org/10.1016/j.dsx.2021.05.019
  9. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases 2021;12:85-9. https://doi.org/10.14740/jmc3637
  10. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021;42:264.e5-8. https://doi.org/10.1016/j.ajem.2020.09.032
  11. Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol 2015;53:248-57. https://doi.org/10.1093/mmy/myu086
  12. Smith HW, Kirchner JA. Cerebral mucormycosis; a report of three cases. AMA Arch Otolaryngol 1958;68:715-26. https://doi.org/10.1001/archotol.1958.00730020739010
  13. Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021;11:1029-30. https://doi.org/10.1002/alr.22785
  14. Saldanha M, Reddy R, Vincent MJ. Title of the article: paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg 2022;74:3407-10. https://doi.org/10.1007/s12070-021-02574-0
  15. Revannavar SM, P S S, Samaga L, V K V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021;14:e241663. https://doi.org/10.1136/bcr-2021-241663
  16. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit 2022;41:616-9. https://doi.org/10.1080/01676830.2021.1903044